Akamis Bio is a biotechnology company founded in 2010. Specializing in the Biotechnology and Health Care industries, it has received a significant $30.00M investment through a Convertible Note investment in 05 January 2023. This investment comes from reputable investors such as Arch Venture Partners, Westlake Village BioPartners, and the Parker Institute for Cancer Immunotherapy.
Akamis Bio
Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer
Founded 2010
Abingdon, United Kingdom
50 employees
Convertible Note
Total: $102.70M
Biotechnology, Health Care +1
Abingdon, United Kingdom
50 employees
Convertible Note
Total: $102.70M
Biotechnology, Health Care +1
General Information
Company Name
Akamis Bio
Founded Year
2010
Location
Abingdon, United Kingdom
Abingdon, United Kingdom
Employees
50
Industries
Biotechnology, Health Care, Health and Wellness
Funding Stage
Convertible Note
Social
BounceWatch is an independent company data service, not affiliated with Akamis Bio. To contact Akamis Bio, visit akamisbio.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Akamis Bio compare?
A PDF of Akamis Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Akamis Bio soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Akamis Bio on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United Kingdom Market
Biotechnology
About Akamis Bio
Funding Rounds & Investors (9)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Convertible Note | $30.00M | 3 |
|
05 Jan 2023 |
| Secondary Market | Undisclosed | 1 |
|
18 Jan 2021 |
| Venture Round | $15.00M | 2 |
|
12 Dec 2017 |
| Series C | £25.00M | 6 |
|
19 May 2015 |
| Grant | $3.30M | - |
|
16 Jan 2013 |
| Series B | £22.00M | 4 |
|
09 Jul 2012 |
| Grant | £1.80M | - |
|
12 Sep 2011 |
| Series A | £5.60M | 2 |
|
08 Mar 2010 |
| Seed Round | Undisclosed | - |
|
01 Jan 2007 |
Akamis Bio Alternatives & Competitors
View All Alternatives
Akamis Bio vs
Lytix Biopharma
Norway
A clinical-stage immuno-oncology company developing proprietary oncolytic drugs as a novel therapy t...
Grant
15 employees
Biotechnology, Health Care
Akamis Bio vs
TME Pharma
Germany
Developing novel therapies for treatment of the most aggressive cancers by acting on the tumor micro...
Post-IPO Equity
12 employees
Biotechnology, Health Care
Akamis Bio vs
MetiMedi Co., Ltd.
Korea South
MetiMedi is developing a first-in-class oral immunotherapeutic small molecule in Phase 2 for solid c...
5 employees
Biotechnology, Health Care
FAQ About Akamis Bio
Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer
Akamis Bio was founded in 2010.
Akamis Bio is headquartered in Abingdon, United Kingdom.
Akamis Bio operates in Biotechnology, Health Care and Health and Wellness.
Akamis Bio has approximately 50 employees.
Akamis Bio has completed 9 funding rounds, raising a total of $102.70M. The latest funding stage is Convertible Note.
Top alternatives and competitors to Akamis Bio include Lytix Biopharma, TME Pharma, MetiMedi Co., Ltd., ImmunoCellular Therapeutics Ltd, Gradalis, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Akamis Bio and Lytix Biopharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Akamis Bio, https://bouncewatch.com/company/akamis-bio, updated 25 November 2024. When citing, please name BounceWatch and link this page.
